Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Evommune, Inc.

NYSE: EVMN · Life Sciences · 7 alerts · CIK 2044725

Share price
$7.10Close, Nov 16
Market cap
$294M
Shares outstanding
41.35MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Evommune, Inc. filings on SEC EDGAR ↗

8:02 AM ET 8-K
Clinical Trial Data

Evommune Clinical Trial Data

Evommune presented Phase 2a proof-of-concept data for EVO301 in patients with moderate-to-severe atopic dermatitis, showing a 55% mean reduction in EASI scores at Week 12 compared to 22% for placebo. The trial validated IL-18 inhibition as a novel therapeutic approach with a favorable safety profile, and the company plans to initiate a Phase 2b dose-ranging trial in mid-2027.

Counterparty
European Academy of Dermatology and Venereology (EADV)
4:06 PM ET 8-K
Clinical Trial Data

Evommune Clinical Trial Data

Evommune announced that Phase 2a proof-of-concept data for EVO301, its IL-18 binding protein candidate for moderate-to-severe atopic dermatitis, will be presented in a late-breaking oral session at the EADV 2026 Congress. The presentation will build on topline results reported earlier in the year as the company prepares to initiate a Phase 2b dose-ranging study in mid-2027.

Counterparty
European Academy of Dermatology & Venereology (EADV)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.